Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

YS Biopharma Says PIKA Rabies Vaccine Effective after One-Week Dosing

publication date: Apr 12, 2024

Beijing’s YS Biopharma reported positive results from the ongoing Phase III clinical trial of its next-gen PIKA Rabies Vaccine. The company said interim results show that the vaccine has met its primary endpoints with potential to offer best-in-class accelerated protection and meet the WHO's goal of a one-week rabies vaccine regimen that would replace the usual three- or four-week regimens. YS Biopharma is a China-US biopharma that develops vaccines and therapeutic biologics for infectious diseases and cancer. More details....

Stock Symbol: (NSDQ: YS)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here